Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis

Barnette, K. Gary; Gordon, Michael; Rodriguez, Domingo; Bird, T. Gary; Skolnick, Alan; Schnaus, Michael; Skarda, Paula K.; Lobo, Suzana M.; Sprinz, Eduardo; Arabadzhiev, Georgi; Kalaydzhiev, Petar; Steiner, Mitchell S.

doi:10.1056/evidoa2200145

Cited by 30 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sabizabulin group showed a 55% relative reduction in deaths compared with the placebo group and statistically significant reductions in the secondary endpoints. 3 Safety findings were similar to those seen in the phase II study: the medication was well tolerated, and the main side effects of the medication were the elevation of the liver function test and diarrhoea. The drug was associated with fewer adverse events than the placebo, and no serious adverse events were attributable to the drug.…”

Section: Q What Were the Design And Eligibility Criteria Of The Veru-...supporting

confidence: 68%

Sabizabulin for the Treatment of Patients Hospitalized with Moderate–Severe COVID-19 (Requiring Oxygen) Who Were at High Risk for Acute Respiratory Distress Syndrome and Death

Skarda¹

2022

US Respiratory &Amp; Pulmonary Diseases

View full text Add to dashboard Cite

Section: Q What Were the Design And Eligibility Criteria Of The Veru-...supporting

confidence: 68%

Sabizabulin for the Treatment of Patients Hospitalized with Moderate–Severe COVID-19 (Requiring Oxygen) Who Were at High Risk for Acute Respiratory Distress Syndrome and Death

Skarda¹

2022

US Respiratory &Amp; Pulmonary Diseases

View full text Add to dashboard Cite

“…Recent publication on sabizabulin shows reduction of more than 50 % in mortality rate among hospitalized COVID-19 patients [133]. The strongest actions of sabizabulin are in its ability to disrupt AR through different pathways, developed for castration-resistant prostate cancer that did not respond to NsAAs [134].…”

Section: Impact Of Drugs That Affect Androgen-mediated Mechanisms In ...mentioning

confidence: 99%

Androgens’ Role in Severity and Mortality Rates of COVID-19

et al. 2022

View full text Add to dashboard Cite

Background and Aim: by the end of December 2019 new corona virus began to spread from Wuhan, China and caused a worldwide pandemic. COVID-19 deaths and prevalence represented sex discrepant patterns with higher rate of deaths and infection in males than females which could be justified by androgen-mediated mechanisms. this review aimed to assess the role of androgens in COVID-19 severity and mortality Discussion: androgens increase expression of Type II transmembrane Serine Protease (TMPRSS2) and Angiotensin Converting Enzyme 2 (ACE2) which both facilitate new corona virus entry into host cell and their expression is higher in young males than females. According to observational studies, prevalence of COVID-19 infections and deaths was more in androgenic alopecic patients than patients without androgenic alopecia. The COVID-19 mortality rates in aged men (>60 years) was substantially higher than aged females and even young males caused by high inflammatory activities such as cytokine storm due to hypogonadism in this population. Use of anti-androgen and TMPRSS2 inhibitor drugs considerably modified COVID-19 symptoms. androgen deprivation therapy also improved COVID-19 symptoms in prostate cancer: overall the role of androgens in severity of COVID-19 and its associated mortality seemed to be very important . So more studies in variety of populations are required to define the absolute role of androgens.

show abstract

“…Because antibiotics that target bacterial and fungal pathogens are futile against viral infection, the current solution against viral infections such as influenza and coronaviruses is primarily through vaccination, whereas effective virus-killing drugs are highly desired but scarce. Whereas western medicine working against COVID remains under development and clinical trials such as sabizabulin [ 19 ], remdesivir [ 20 ], hydroxychloroquine [ 21 ], and PNPs with anti-viral activities have been reported as effective to contain viral replication and alleviate patient symptoms. For example, flavonoids such as neo-hesperidin, hesperidin, baicalin, kaempferol 3- O -rutinoside, and rutin from different sources, and a series of xanthones from Swertia plants could effectively interact with SARS-CoV-2 targets [ 22 ].…”

Section: Natural Products In Medicinal Plants: Hidden Treasures With ...mentioning

confidence: 99%

Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era

Guo¹,

Yao

Chen³

et al. 2022

Horticulture Research

View full text Add to dashboard Cite

Globally, medicinal plant natural products (PNPs) are a major source of substances used in traditional and modern medicine. As we human race face tremendous public health challenge posed by emerging infectious diseases, antibiotic resistance and surging drug prices etc., harnessing the healing power of medicinal plants gifted from mother nature is more urgent than ever in helping us survive future challenge in a sustainable way. PNP research efforts in pre-genomic era focus on discovering bioactive molecules with pharmaceutical activities, and identifying individual genes responsible for biosynthesis. Critically, systemic biological, multi- and inter-disciplinary approaches integrating and interrogating all accessible data from genomics, metabolomics, structural biology and chemical informatics, are necessary to accelerate the full characterization of biosynthetic and regulatory circuitry for producing PNPs in medicinal plants. In this review, we attempt to provide a brief update on the current research of PNPs in medicinal plants by focusing on how different state-of-the-art biotechnologies facilitate their discovery, the molecular basis of their biosynthesis, as well as synthetic biology. Finally, we humbly provide a foresight of the research trend for understanding the biology of medicinal plants in the coming decades.

show abstract

Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis

Cited by 30 publications

References 27 publications

Sabizabulin for the Treatment of Patients Hospitalized with Moderate–Severe COVID-19 (Requiring Oxygen) Who Were at High Risk for Acute Respiratory Distress Syndrome and Death

Sabizabulin for the Treatment of Patients Hospitalized with Moderate–Severe COVID-19 (Requiring Oxygen) Who Were at High Risk for Acute Respiratory Distress Syndrome and Death

Androgens’ Role in Severity and Mortality Rates of COVID-19

Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era

Contact Info

Product

Resources

About